Summer Sale
50% off Premium Yearly
00days
00hrs
00mins
00secs
NYSE:PFE
Pfizer Inc (PFE)
26.17
+0.57 (2.23%)
as of Jun 11, 2026, 8:00:00 pm Market Open.
322 watching
Financials 
Technical Analysis 0
TOP PICK
(A Top Pick May 10/06. Up 5.3%.) One of the cheapest stocks on the S&P500. His model price is $40.47 giving it a 55% positive differential. Any positive catalyst will help the stock price. Dividends are almost 5%.
Brian Acker, CAOwned
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick Dec 5/06. Up to .3%.) Still has lots of upside and it has a good yield. Have a lot of cash.
Norman LevineOwned
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick Dec 21/06. Down 2.5%.) Sold their consumer business. There is so much value there. New management is cutting costs. 4.7% dividend. Still likes.
Brian Acker, CAOwned
biotechnologypharmaceutical
BUY
Pays a nice dividend. Have tons of cash through their normal cash generation as well as selling their consumers product division. Using some of it to increase dividends and some to buy back shares. 13 X earnings.
Norman LevineOwned
biotechnologypharmaceutical
TOP PICK
This is a balance sheet story. They have a huge balance sheet that they can’t do anything with. Volatility in the stock price has fallen. New management wants to fire 10,000 people, etc. and it sounds like he wants to reduce the balance sheet. A restructuring story. 5% dividend. His current model price is $40, a 51% positive differential.
Brian Acker, CAOwned
biotechnologypharmaceutical
BUY
Like many of the pharmaceuticals, it is a company in transition. Won't go up aggressively, but it pays a decent yield. Historically, these companies have done well and they throw off a lot of free cash flow. New management is expected to cut costs and the company is buying back stock. Good balance sheet. Cheap.
Paul Harris, CFAOwned
biotechnologypharmaceutical
TOP PICK
His model price is $39. That’s a 49% positive differential. Looking out 1 year with their earnings, it’s a 15% return, plus the dividend of 4.4% gives a 20% implied rate of return.
Brian Acker, CAOwned
biotechnologypharmaceutical
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
